drugset / Trial / NCT03697668
Triple Antimalarial Combination to Accelerate the Parasite Clearance and to Prevent the Selection of Resistant Parasites
Phase 2
Unknown
50 enrolled
Nurex S.r.l.
Purdue University · collabUniversità degli Studi di Sassari · collabVinmec Healthcare System · collab
RandomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to provide a new drug combination for a better treatment of P. falciparum for a faster parasite clearance and to counteract artemisinin resistance.
Timeline
- Start
- 2017-09-17
- Primary completion
- 2018-12-31
- Completion
- 2019-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | ARTENIMOL | Small molecule | — | — |
| Subject | Imatinib | Small molecule | — | — |
| Comparator | piperaquine | Small molecule | — | — |